Pretreatment late-phase DCE-MRI predicts outcome in locally advanced cervix cancer

Kjersti V. Lund, Trude G. Simonsen, Gunnar B. Kristensen, Einar K. Rofstad

Supplementary Table 1

Patient characteristics ($N = 80$).

Characteristic	
Age, years	
Median	57
Range	22−88
Histology, number of patients	
Squamous cell carcinoma	68
Adenocarcinoma	10
Undifferentiated	2
Volume, cm^3	
Median	40.7
Range	2.1−319
FIGO stage, number of patients	
I	7
II	55
III	15
IV	3
Pelvic lymph node status, number of patients	
Positive	35
Negative	45

Supplementary Table 2

Multivariate Cox regression analysis of clinical and SITC parameters together with LETV.

	Disease-free survival				Overall survival			
	p-values				p-values			
Tumor volume	0.93	0.83	0.80	0.96	0.88	0.99	0.96	0.80
FIGO stage	0.053	**0.047**	0.050	0.051	0.082	0.066	0.082	0.073
Lymph node status	0.72	0.68	0.74	0.78	0.75	0.80	0.78	0.69
LETV (EF-method)	**0.025**	0.085	0.26	0.098	**0.0022**	**0.0077**	0.057	**0.019**
TVDS	0.89				0.73			
TFDS		0.23				0.14		
TVIS			0.73				0.87	
TFIS				0.26				0.27

p-values refer to multivariate regression analyses involving tumor volume, FIGO stage, lymph node status, LETV (EF-method), and either TVDS, TFDS, TVIS, or TFIS. SITC, signal intensity *versus* time curve; LETV (EF-method), low enhancing tumor volume (enhancing fraction method); TVDS, tumor volume with decreasing signal; TFDS, tumor fraction with decreasing signal; TVIS, tumor volume with increasing signal; TFIS, tumor fraction with increasing signal.

Supplementary Table 3

Multivariate Cox regression analysis of clinical and late-phase SITC parameters together with LETV.

	Disease-free survival				Overall survival			
	p-values				p-values			
Tumor volume	0.99	0.95	0.88	0.91	0.96	0.85	0.81	0.66
FIGO stage	0.053	**0.046**	**0.048**	0.050	0.083	0.064	0.080	0.070
Lymph node status	0.75	0.69	0.77	0.80	0.70	0.75	0.71	0.64
LETV (SI-method)	**0.048**	0.15	0.47	0.17	**0.0036**	**0.014**	0.12	**0.033**
TVDS	0.93				0.68			
TFDS		0.21				0.14		
TVIS			0.53				0.91	
TFIS				0.23				0.27

p-values refer to multivariate regression analyses involving tumor volume, FIGO stage, lymph node status, LETV (SI-method), and either TVDS, TFDS, TVIS, or TFIS. SITC, signal intensity *versus* time curve; LETV (SI-method), low enhancing tumor volume (signal intensity method); TVDS, tumor volume with decreasing signal; TFDS, tumor fraction with decreasing signal; TVIS, tumor volume with increasing signal; TFIS, tumor fraction with increasing signal.

Supplementary Table 4

Multivariate Cox regression analysis of clinical and late-phase SITC parameters together with LETF.

	Disease-free survival				Overall survival			
	p-values				p-values			
Tumor volume	0.65	0.58	1.00	0.44	0.58	0.20	0.51	0.12
FIGO stage	0.060	**0.049**	**0.044**	0.057	0.093	0.066	0.060	0.074
Lymph node status	0.69	0.64	0.78	0.79	0.81	0.83	0.66	0.66
LETF (SI-method)	0.16	0.45	0.51	0.55	**0.0021**	**0.025**	**0.043**	**0.038**
TVDS	0.98				0.34			
TFDS		0.16				0.14		
TVIS			0.12				0.091	
TFIS				0.19				0.20

p-values refer to multivariate regression analyses involving tumor volume, FIGO stage, lymph node status, LETF (SI-method), and either TVDS, TFDS, TVIS, or TFIS. SITC, signal intensity *versus* time curve; LETF (SI-method), low enhancing tumor fraction (signal intensity method); TVDS, tumor volume with decreasing signal; TFDS, tumor fraction with decreasing signal; TVIS, tumor volume with increasing signal; TFIS, tumor fraction with increasing signal.